[1] Lerner L B, Vary K T, Barry M J, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: aua guideline part I-initial work-up and medical management[J]. J Urol, 2021, 206(4): 806-817.
[2] Csikós E, Horváth A, Ács K, et al. Treatment of benign prostatic hyperplasia by natural drugs[J]. Molecules, 2021, 26(23): 7141.
[3] Miñana B, Molero J M, Agra R A, et al. Real-world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain[J]. Int J Clin Prac, 2021, 75(8): e14250.
[4] Low P, Li K D, Hakam N, et al. 5-Alpha reductase inhibitor related litigation: a legal database review[J]. Andrology, 2022, 10(3): 470-476.
[5] Yu Z J, Yan H L, Xu F H, et al. Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia[J]. Front Pharmacol, 2020, 11(5): 658.
[6] Jin R, Strand D W. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms[J]. Prostate, 2021, 81(13): 944-955.
[7] Lulic Z, Son H, Yoo S B, et al. Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in south korea: analysis of drug utilization and adverse events using the national health insurance review and assessment service database[J]. BMC Urol, 2021, 21(1): 178.
[8] Roehrborn C G, Rukstalis D B. Prostatic urethral lift versus medical therapy: examining the impact on sexual function in men with benign prostatic hyperplasia[J]. Eur Urol Focus, 2022, 8(1): 217-227.
[9] Ciríaco S L, Carvalho I P S, Alves T N J, et al. Development of microemulsion of tamsulosin and dutasteride for benign prostatic hyperplasia therapy[J]. Colloids Surf B, 2020, 185(1): 110573.
[10] Matsukawa Y, Takai S, Funahashi Y, et al. Effects of withdrawing α1-blocker from combination therapy with α1-blocker and 5α-reductase inhibitor in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective and comparative trial using urodynamics[J]. J Urol, 2017, 198(4): 905-912.
[11] Jin S, Xiang P, Liu J, et al. Activation of cGMP/PKG/p65 signaling associated with PDE5-Is downregulates CCL5 secretion by CD8⁺ T cells in benign prostatic hyperplasia[J]. Prostate, 2019, 79(8): 909-919.
[12] Wada N, Abe N, Miyauchi K, et al. Dutasteride add-on treatment to tadalafil for patients with benign prostatic enlargement is similarly effective as dutasteride add-on treatment to alpha blocker: a propensity-score matching analysis[J]. Int Urol Nephrol, 2022, 54(6): 1193-1198.
[13] Watanabe D, Yamashita A, Miura K, et al. Effects on sexual function in Japanese patients with benign prostatic hyperplasia upon switching from combination therapy with α1 blocker and dutasteride to combination therapy with tadalafil and dutasteride[J]. Aging Male, 2020, 23(5): 501-506.
[14] Wiedemann A, Dündar V, Heese M, et al. Adverse drug reaction affecting the urinary tract-the witten urinary tract adverse reaction score[J]. Aktuelle Urol, 2021, 52(5): 481-489.
[15] Kosilov K, Kuzina I, Kuznetsov V, et al. The risk of sexual dysfunction and effectiveness of treatment of benign prostatic hyperplasia with severe lower urinary tract dysfunction with combination of dutasteride and solifenacin[J]. J Sex Med, 2018, 15(11): 1579-1590.
[16] Kosilov K, Kuzina I, Kuznetsov V, et al. Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients[J]. Asian J Urol, 2022, 9(1): 42-50.
[17] Yamanishi T, Asakura H, Seki N. A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms(DIrecT study)[J]. Low Urin Tract Symptoms, 2019, 11(3): 115-121.
[18] Tsunemori H, Sugimoto M. Effects of inflammatory prostatitis on the development and progression of benign prostatic hyperplasia: a literature review[J]. Int J Urol, 2021, 28(11): 1086-1092.
[19] Gong Y C, Chen X, Song Q T, et al. A randomized placebo-controlled study: phellodendron Bawei tablets combined with standard management can improve storage symptoms, sleep quality, and medication compliance in patients with benign prostatic hyperplasia compared to placebo with standard management[J]. Transl Androl Urol, 2021, 10(8): 3423-3431.
[20] Choi B R, Kim H K, Soni K K, et al. Additive effect of oral LDD175 to tamsulosin and finasteride in a benign prostate hyperplasia rat model[J]. Drug Des Devel Ther, 2018, 12(6): 1855-1863.
[21] Karunasagara S, Hong G L, Jung D Y, et al. Protective effects of combination of stauntonia hexaphylla and cornus officinalis on testosterone-induced benign prostatic hyperplasia through inhibition of 5α-reductase type 2 and induced cell apoptosis[J]. PLoS One, 2020, 15(8): e0236879.
[22] Stritt K, Bosshard P, Roth B, et al. Benign prostatic hyperplasia treatment: surgical alternatives to transurethral resection of the prostate[J]. Rev Med Suisse, 2021, 17(761): 2074-2076.
[23] Bansal A, Arora A. Transurethral resection of prostate and bleeding: a prospective, randomized, double-blind placebo-controlled trial to see the efficacy of short-term use of finasteride and dutasteride on operative blood loss and prostatic microvessel density[J]. J Endourol, 2017, 31(9): 910-917.
[24] Dutt U K, Kumar S, Dorairajan L N, et al. Effect of preoperative finasteride on perioperative blood loss during transurethral resection of the prostate and on microvessel density in patients with benign prostatic hyperplasia: an open label randomized controlled trial[J]. Urol Ann, 2021, 13(3): 199-204.
[25] 刘 浩, 王 杰, 宋向成, 等. 经尿道前列腺切除术联合爱普列特与非那雄胺片治疗良性前列腺增生的临床疗效[J]. 当代医学, 2022, 28(14): 155-158.
[26] Li X, Li B, Ullah M W, et al. Water-stable and finasteride-loaded polyvinyl alcohol nanofibrous particles with sustained drug release for improved prostatic artery embolization in vitro and in vivo evaluation[J]. Mater Sci Eng C Mater Biol Appl, 2020, 115(10): 111107.
[27] Ghahhari J, De N C, Lombardo R, et al. Efficacy and efficiency of Green-Light XPS 180-watt laser system for benign prostatic enlargement in patients treated with 5α-reductase inhibitors[J]. Eur Rev Med Pharmacol Sci, 2021, 25(13): 4527-4534.
[28] Sachdeva R, Kaur N, Kapoor P, et al. Computational analysis of protein-protein interaction network of differentially expressed genes in benign prostatic hyperplasia[J]. Mol Biol Res Commun, 2022, 11(2): 85-96.
[29] Chen S F, Li C X, Geng Q. The mechanism of Lingze tablets in the treatment of benign prostatic hyperplasia based on network pharmacology and molecular docking technology[J]. Andrologia, 2022, 9(5): e14555.
[30] Miernik A, Roehrborn C G. Benign prostatic hyperplasia treatment on its way to precision medicine: dream or reality?[J]. Eur Urol Focus, 2022, 8(2): 363-364.